Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This study is a phase I clinical trial aimed to determine the recommended dose of
[131I]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma
(binding [131I]ICF01012 ). The [131I]ICF01012 is a targeted radionuclide therapy with a high
affinity for melanin.